Are Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) shares too expensive at this price?

In the latest session, Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) closed at $25.44 up 1.48% from its previous closing price of $25.07. In other words, the price has increased by $+0.37 from its previous closing price. On the day, 1045142 shares were traded. SNDX stock price reached its highest trading level at $26.07 during the session, while it also had its lowest trading level at $24.76.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored

Ratios:

For a deeper understanding of Syndax Pharmaceuticals Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 17.20 and its Current Ratio is at 17.20. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

On April 11, 2022, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $31.

On February 15, 2022, Goldman started tracking the stock assigning a Buy rating and target price of $37.Goldman initiated its Buy rating on February 15, 2022, with a $37 target price.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 02 when Ordentlich Peter sold 17,200 shares for $25.05 per share. The transaction valued at 430,936 led to the insider holds 265 shares of the business.

Ordentlich Peter sold 7,800 shares of SNDX for $195,089 on Dec 01. The Chief Scientific Officer now owns 265 shares after completing the transaction at $25.01 per share. On Oct 06, another insider, Metzger Michael A, who serves as the Chief Executive Officer of the company, sold 16,231 shares for $25.29 each. As a result, the insider received 410,508 and left with 17,659 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 12.08 while its Price-to-Book (P/B) ratio in mrq is 4.57.

Stock Price History:

Over the past 52 weeks, SNDX has reached a high of $26.51, while it has fallen to a 52-week low of $13.27. The 50-Day Moving Average of the stock is 23.18, while the 200-Day Moving Average is calculated to be 19.93.

Shares Statistics:

For the past three months, SNDX has traded an average of 721.20K shares per day and 531.57k over the past ten days. A total of 60.67M shares are outstanding, with a floating share count of 57.43M. Shares short for SNDX as of Oct 13, 2022 were 4.48M with a Short Ratio of 4.18M, compared to 4.6M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 7.91% and a Short% of Float of 8.02%.

Earnings Estimates

There are 6 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.63 for the current quarter, with a high estimate of -$0.6 and a low estimate of -$0.66, while EPS last year was -$0.4. The consensus estimate for the next quarter is -$0.78, with high estimates of -$0.64 and low estimates of -$0.88.

Analysts are recommending an EPS of between -$2.63 and -$3.04 for the fiscal current year, implying an average EPS of -$2.79. EPS for the following year is -$3, with 7 analysts recommending between -$2.76 and -$3.32.